← FDA DRUG APPROVALS

FDA ANDA · ANDA209677

TERIFLUNOMIDE

Sponsor: SOLA PHARMS

APPLICATION
ANDA209677
TYPE
ANDA
ORIGINAL APPROVAL
2020-06-17
LATEST ACTION
2025-03-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

TERIFLUNOMIDEPrescription
TERIFLUNOMIDE 7MG · TABLET · ORAL
TERIFLUNOMIDEPrescription
TERIFLUNOMIDE 14MG · TABLET · ORAL

Approval history

2025-03-07Labeling · Supplement 3 · standardAP
2025-03-07Labeling · Supplement 2 · standardAP
2023-09-28UNKNOWN · Original · standardLetterAP
2020-06-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →